Last reviewed · How we verify
Natriuretic peptides
Natriuretic peptides is a Small molecule drug developed by Danish Headache Center. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Natriuretic peptides |
|---|---|
| Sponsor | Danish Headache Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CANF-Comb-II PET-MR in Atherosclerosis Multisite
- ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure (NA)
- A Study of Ponsegromab in People With Heart Failure (PHASE2)
- Vosoritide for Selected Genetic Causes of Short Stature (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia (PHASE2)
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (PHASE3)
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natriuretic peptides CI brief — competitive landscape report
- Natriuretic peptides updates RSS · CI watch RSS
- Danish Headache Center portfolio CI
Frequently asked questions about Natriuretic peptides
What is Natriuretic peptides?
Who makes Natriuretic peptides?
What development phase is Natriuretic peptides in?
Related
- Manufacturer: Danish Headache Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing